WELWYN GARDEN CITY, England, November 10 /PRNewswire/ --

- Award-Winning UK Research Leads to First new Category of Drugs in Anaesthesia Medicine in the Last Two Decades

TEL AVIV, Israel, November 10 /PRNewswire/ -- InspireMD, developers of the novel MGuard(TM) coronary stent system, announced today that MGuard(TM) was successfully implanted in a complex lesion in a live case at the TCT '08. The procedure was performed by Dr. Dariusz Dudek and was broadcast from Krakow, Poland. Additionally, InspireMD's Breakfast Meeting Symposium A New Approach to Treating Thrombus Containing Lesions (ACS, AMI and SVG) was met with great enthusiasm and excitement. Some of the world's leading interventional cardiologists and opinion leaders were among the speakers at the MGuard(TM) symposium and included Alexandre Abizaid MD, Yaron Almagor MD, Carlo Di Mario MD, Martin Leon MD, and Chaim Lotan MD.

LONDON, November 10 /PRNewswire/ --

- Remembering the Two Great Wars, London Lawyer Sends Wake-Up Call to the World's Governments and Learned Bodies

International lawyer and world-affairs analyst, William Dunmore, (a grandfather and 2nd World War naval officer), has deep concerns for the children and future generations whose interests have been completely ignored in this troubled, money-mad world, where we are all sleep-walking into a crematorium.

Tomorrow he is, therefore, contacting all UNO, UNESCO and UNICEF permanent delegates and some 25,000 seats of learning by e-mail, with a unique Anti-Causal Plan For Rescuing The Young From The Dire Peril, namely, a Potential Third World War and Nuclear Doomsday.

PARIS, November 10 /PRNewswire/ --

Airsavings, the global leader in ancillary revenue development for low-cost airlines, has launched an innovative ancillary revenue platform called Privilege Outlet. The industry-first program attracts passengers through invitation-only online sales, featuring designer and name brand labels (Guess, Lacoste, Diesel etc.) with discounts of 30-70% off. Privilege Outlet, by providing passengers with an attractive, invitation-based option for mile accumulation and redemption, has created a powerful additional ancillary revenue stream for airlines while creating frequent flier programs that are wanted and viable again.

MUMBAI, India, November 10 /PRNewswire/ --

- Ashorne Hill and Tata Interactive Systems Join Hands to Enable Key Organisational Initiatives

Now both Ashorne Hill and Tata Interactive Systems, part of the $70 billion Tata Group, have come together to provide a range of bespoke Learning Solutions designed to help organisations address and support key business challenges.

Announcing the alliance, John Carson, Managing Director of Ashorne Hill said, The combination of Ashorne Hill's highly experienced Learning Development capability and Tata Interactive Systems' Learning Technology expertise will enable us to support our clients with solutions that enable employees to impact and deliver measurable results back into the business.

SAN FRANCISCO, November 10 /PRNewswire/ --

- Find out what's hot in Hollywood at blinkx.com

blinkx, the world's largest video search engine, today announced a content partnership with People.com, the leading celebrity news site. Under the terms of the agreement, blinkx has added People.com's high-quality, original video programming to its ever-expanding index.

OSLO and FOSTER CITY, California, November 10 /PRNewswire/ --

- India Chosen as First Commercial Market to Demonstrate Test's Potential for Rapid Uptake

DiaGenic ASA (OSL: DIAG) and Applied Biosystems Inc. (NYSE: ABI) today announced the launch of BCtect(TM), a blood-based test for early detection of breast cancer. The test searches for a unique gene expression signature identified by DiaGenic using a custom TaqMan(R) Array manufactured for DiaGenic by Applied Biosystems. India was chosen as the first country for the introduction of BCtect(TM) after successful completion of a large study in the country.

NOVATO, California, November 10 /PRNewswire/ --

Raptor Pharmaceuticals Corp. (Raptor or the Company) (OTC Bulletin Board: RPTP), today announced that the Company has entered into an agreement with the Centre Hospitalier Universitaire d'Angers (CHU d'Angers) of France to evaluate Raptor's proprietary delayed-release cysteamine bitartrate (DR Cysteamine) in a Phase II clinical trial in patients with Huntington's Disease (Huntington's). CHU d'Angers has received a grant from the Programme Hospitalier de Recherche Clinique - National, a program under the French Ministry of Health, to fund the two-year, multi-center Phase II clinical trial in Huntington's patients. Under the terms of the agreement, Raptor will provide clinical supplies of DR Cysteamine for the trial.

CAMBRIDGE, England, November 10 /PRNewswire/ --

- The European Hands-On Science Research Programme Brings the Amgen Foundation's Total Commitment to Amgen Scholars to 27.5 Million USD

The Amgen Foundation and the University of Cambridge, along with two other leading European universities, today announced the launch of Amgen Scholars Europe, a 2.5 million USD, two-year programme that will provide more than 100 selected undergraduate students from throughout Europe the opportunity to engage in a hands-on summer research experience under top academic scientists at three world class universities.

BASEL, Switzerland, November 10 /PRNewswire/ --

- Results Demonstrate Effective and Simplified Approach to Anaemia Management in Chronic Kidney Disease Patients on Dialysis

Interim study results from 90 renal centres in Germany confirm for the first time that in a real-life setting Mircera(R) maintains haemoglobin (Hb) levels within a narrow range when chronic kidney disease (CKD) patients receiving dialysis are switched to once-monthly Mircera from commonly used and frequently dosed erythropoiesis-stimulating agents (ESAs)(1).

Multimedia News Release: http://www.prnewswire.com/mnr/mircera/35922/